As per reports, Eli Lilly & Company and Amgen have entered an agreement for a global antibody manufacturing to increase global supply capacity for Lilly’s potential COVID-19 treatments. Lilly is currently researching a number of potential neutralizing antibodies for the prevention/treatment or both for COVID-19, either as monotherapy or in combination.
The collaboration between the companies will benefit to scale up production and serve more patients globally if Lilly’s antibody therapies succeed and receive approval.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.